Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· December 3, 2025

Allison Ames, Susan Brandt, Steven Ekstract, Hallmark, Dolly Parton, and Kevin Smith Join Licensing International Hall of Fame

View original at globenewswire.com
Allison Ames, Susan Brandt, Steven Ekstract, Hallmark, Dolly Parton, and Kevin Smith Join Licensing International Hall of Fame NEW YORK, Dec…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Dolly Parton's Imagination Library has donated over 302 million books

    80% confidence
  • From industry veterans to global icons, this year's nominees represent the wide-ranging possibilities of brand licensing and its influence across sectors

    80% confidence
  • Dolly Parton has sold more than 100 million records worldwide

    80% confidence
  • The global licensing industry is valued at $369+ billion

    80% confidence
  • The Hall of Fame event unites our global community of leaders and underscores the far-reaching impact of licensing worldwide

    80% confidence
  • The Dr. Seuss brand has grown into a multibillion-dollar franchise under Susan Brandt's leadership

    80% confidence
  • Beanstalk accounted for over $11 billion in retail sales on behalf of its clients in 2024

    80% confidence
  • We're proud to recognize such influential leaders while also celebrating emerging talent through our annual Rising Star Award and the Licensing International Foundation's scholarship program

    80% confidence
  • Under Allison Ames' leadership, Beanstalk has won over 30 industry awards

    80% confidence
  • Beanstalk consistently ranks as the third largest licensing agency in the industry

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com